Ensoma

Ensoma is a private, pre-clinical stage biotech developing a novel in vivo platform for engineering hematopoietic stem cells (HSCs). Its technology aims to supersede complex ex vivo cell therapies by delivering genetic tools directly to a patient's HSCs, enabling durable, off-the-shelf treatments for genetic, hematologic, and oncologic diseases. The company is advancing lead programs in X-linked chronic granulomatous disease (X-CGD), sickle cell disease, and solid tumors, supported by top-tier investors. Ensoma's approach promises to simplify the patient treatment journey and scale manufacturing to serve large global populations.

Proprietary in vivo platform combining engineered, off-the-shelf virus-like particles (VLPs) that target hematopoietic stem cells (HSCs) with a sophisticated gene engineering toolkit (including CRISPR-Cas and base editors) for precise, durable genetic modifications.

Ensoma competes in the advanced gene and cell therapy space. Direct competitors include companies developing in vivo gene editing (e.g., using lipid nanoparticles or other vectors) and companies advancing next-generation ex vivo HSC therapies (e.g., Bluebird Bio, Vertex/CRISPR Therapeutics, Graphite Bio). Ensoma's differentiation lies in its specific HSC-targeted VLP delivery and its aim for multifunctional, durable in vivo engineering of the entire hematopoietic system.